What question did this study set out to answer?

This trial aimed to determine if lowering cholesterol levels can reduce the risk of coronary heart disease in men with primary hypercholesterolemia.

January 20, 1984

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

Key Points

This trial aimed to determine if lowering cholesterol levels can reduce the risk of coronary heart disease in men with primary hypercholesterolemia.
Multicenter, randomized, double-blind trial with 3,806 middle-aged men with type II hyperlipoproteinemia.
Cholestyramine resin treatment versus placebo for an average of 7.4 years.
Both groups followed a moderate cholesterol-lowering diet.
Cholestyramine group achieved 13.4% reduction in total cholesterol and 20.3% reduction in LDL-C.
Cholestyramine reduced risk of primary endpoint (CHD death or nonfatal myocardial infarction) by 19% (P<0.05).
Cumulative incidence of primary endpoint was 7% in cholestyramine vs 8.6% in placebo group.

Abstract

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (PJAMA1984;251:351-364)

AI से पूछें

Bookmark